Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Loss of PRDM11 promotes MYC-driven lymphomagenesis

Research output: Contribution to journalJournal articleResearchpeer-review

  1. A small change makes a big difference in Hodgkin lymphoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Treatment dilemmas in asymptomatic children with primary hemophagocytic lymphohistiocytosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Defective TAFI activation in hemophilia A mice is a major contributor to joint bleeding

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Epigenetic therapy in hematological cancers

    Research output: Contribution to journalReviewResearchpeer-review

  2. Proinflammatory CD20+ T cells in the pathogenesis of multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Mother-child transmission of epigenetic information by tunable polymorphic imprinting

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

The PR-domain (PRDM) family of genes encodes transcriptional regulators, several of which are deregulated in cancer. By using a functional screening approach, we sought to identify novel tumor suppressors among the PRDMs. Here we demonstrate oncogenic collaboration between depletion of the previously uncharacterized PR-domain family member Prdm11 and overexpression of MYC. Overexpression of PRDM11 inhibits proliferation and induces apoptosis. Prdm11 knockout mice are viable, and loss of Prdm11 accelerates MYC-driven lymphomagenesis in the Eµ-Myc mouse model. Moreover, we show that patients with PRDM11-deficient diffuse large B-cell lymphomas (DLBCLs) have poorer overall survival and belong to the nongerminal center B-cell-like subtype. Mechanistically, genome-wide mapping of PRDM11 binding sites coupled with transcriptome sequencing in human DLBCL cells evidenced that PRDM11 associates with transcriptional start sites of target genes and regulates important oncogenes such as FOS and JUN. Hence, we characterize PRDM11 as a putative novel tumor suppressor that controls the expression of key oncogenes, and we add new mechanistic insight into B-cell lymphomagenesis.

Original languageEnglish
JournalBlood
Volume125
Issue number8
Pages (from-to)1272-81
Number of pages10
ISSN0006-4971
DOIs
Publication statusPublished - 19 Feb 2015

    Research areas

  • Animals, Carrier Proteins, Cell Transformation, Neoplastic, Cells, Cultured, Embryo, Mammalian, Gene Deletion, Gene Expression Regulation, Neoplastic, Gene Knockout Techniques, HEK293 Cells, HeLa Cells, Humans, Lymphoma, Lymphoma, Large B-Cell, Diffuse, Mice, Molecular Sequence Data, Proto-Oncogene Proteins c-myc, Tumor Suppressor Proteins

ID: 45690474